Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ozan Pamir Insider Profile
4 Followers
Ozan Pamir, CFO at 180 Life Sciences, holds 2.91K shares in Chromadex (Ticker: CDXC), holds 8.98K shares in 180 Life Sciences (Ticker: ATNF). Most recently, Ozan Pamir Bought ― shares of Chromadex on Nov 25, 2024 for an estimated value of 21.40K.
Profitable Transactions
0 out of 2 Profitable Transactions
Average Return
-92.90%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Most Profitable Insider Trade
The most profitable trade made by Ozan Pamir
Ozan Pamir's Trading History
180 Life Sciences
May 19, 2023
CFO
Informative Buy
5.21K
$19.94K
Chromadex
Nov 25, 2024
CFO
Informative Buy
21.40K
$21.69K
List of latest transactions for each holding click on a transaction to see Ozan Pamir's performance on stock
You May Also Like
Ozan Pamir insider profile FAQ
What is the percentage of profitable transactions made by Ozan Pamir?
The percentage of profitable transactions made by Ozan Pamir is 0%.
What is the average return per transaction made by Ozan Pamir?
The average return per transaction made by Ozan Pamir is -92.90%.
What stocks does Ozan Pamir hold?
Ozan Pamir holds: ATNF, CDXC stocks.
What was Ozan Pamir’s latest transaction?
Ozan Pamir latest transaction was an Informative Buy of $21.40K.
What was Ozan Pamir's most profitable transaction?
Ozan Pamir’s most profitable transaction was an Informative Buy of ATNF stock on December 13, 2021. The return on the trade was -92.60%.
What is Ozan Pamir's role in 180 Life Sciences?
Ozan Pamir's role in 180 Life Sciences is CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.